SCHEMBL20154560

SCHEMBL20154560

CN1CC2CC(C1)N2C(=O)c1ccc(C(F)(F)F)nc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.44
KCNH2 Q12809 2/20 0.43
DPP4 P27487 1/20 0.43
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
CNR2 P34972 1/20 0.41
ELOVL6 Q9H5J4 1/20 0.40
STAT3 P40763 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TRPV4 Q9HBA0 2/20 0.38
HRH3 Q9Y5N1 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
USP30 Q70CQ3 1/20 0.38
VNN1 O95497 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23555257 0.86 RET (0.44) RETKCNH2DPP4HTR1AHTR1D
SCHEMBL20148716 0.86 DPP4 (0.43) RETKCNH2DPP4HTR1AHTR1D
SCHEMBL20070573 0.83 KCNH2 (0.45) RETKCNH2DPP4CNR2ELOVL6
SCHEMBL20070453 0.81 RET (0.34) RETSTAT3TRPV4VNN1
SCHEMBL20069586 0.81 HDAC1 (0.43) RETCNR2
SCHEMBL18713231 0.78 NNMT (0.49) RETKCNH2
SCHEMBL20070566 0.78 RET (0.44) RETHTR1AJAK2JAK1HRH3
SCHEMBL20069576 0.77 RET (0.46) RETHRH3
SCHEMBL20069572 0.74 RET (0.52) RET
SCHEMBL20070454 0.73 RET (0.52) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
EP-3523301-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-05-27 EP disclosed
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF RET 1/4885KCNH2 4165/4885DPP4 1948/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885KCNH2 4165/4885DPP4 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.